Jiao Lan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jiao Lan has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Jifei Miao
Shenzhen Bao’an Chinese Medicine Hospital, Guangzhou University of Chinese Medicine, Shenzhen
3 shared publications - Beibei Zhao
Shenzhen Baoan District Hospital of Traditional Chinese Medicine, Shenzhen, China
2 shared publications Shiming Liu
Shenzhen Bao'an Chinese Medicine Hospital, The Seventh Clinical College of Guangzhou University of Chinese Medicine, Shenzhen
2 shared publicationsYiwen Li
Shenzhen Bao'an Chinese Medicine Hospital, The Seventh Clinical College of Guangzhou University of Chinese Medicine, Shenzhen
2 shared publicationsAisi Huang
Shenzhen BaoAn Traditional Chinese Medicine Hospital, Guangzhou University of Chinese Medicine
1 shared publicationBixia Lin
Shenzhen Baoan Traditional Chinese Medicine Hospital, Guangzhou University of Chinese Medicine, Shenzhen, China
1 shared publication
Latest Publications
- Open Access
- 17 August 2026
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 18, 1915244
P2X7 receptor-dependent microglia-astrocyte coupling in Alzheimer's disease: from eATP sensing to synaptic and proteostatic failure
Alzheimer's disease (AD) is characterized not only by amyloid-β and tau pathology but also by progressive failure of multicellular homeostasis. The P2X7 receptor (P2X7R), a low-affinity ATP-gated ion channel preferentially activated in extracellular ATP-rich pathological microenvironments, is well positioned to translate local tissue stress into sustained glial dysfunction. Although P2X7R has traditionally been studied as a microglial inflammasome-associated receptor, its broader significance may lie in coupling microglial activation to astrocytic loss of homeostatic support. In this review, we propose an integrative model in which P2X7R functions as a high-threshold inter-glial transducer through five interconnected axes: extracellular ATP amplification, cytokine relay, extracellular vesicle exchange, convergent synaptic modulation and circuit destabilization, and a coordinated clearance-to-retention switch. Microglial P2X7R activation promotes cytokine and reactive oxygen species production, vesicle and mitochondrial release, inflammatory reprogramming, and impaired phagocytic and lysosomal competence. Astrocytic P2X7R may reinforce this environment through feed-forward ATP release, altered gliotransmission, reactive transformation, extracellular vesicle shedding, and disrupted autophagic and lysosomal processing. We further situate this reciprocal loop within the amyloid plaque niche, where dystrophic neurites, stressed synapses, and reactive glia may create a spatially restricted P2X7R-sensitive ATP microdomain. The resulting cross-glial amplification is proposed to connect neuroinflammation with synaptic destabilization and defective proteostasis. This framework also suggests that brain-penetrant and pharmacologically selective P2X7R antagonists could complement protein-targeted therapies, particularly when guided by functional biomarkers of receptor activity. However, the proposed coupling architecture remains an integrative and testable hypothesis because much of the supporting evidence derives from non-AD models, in vitro studies, or correlative human tissue analyses. Cell-type-specific, temporally resolved studies are therefore required to establish whether P2X7R-dependent microglia–astrocyte coupling causally drives AD progression.
- 17 August 2026
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 18, 1915244
Open AccessP2X7 receptor-dependent microglia-astrocyte coupling in Alzheimer's disease: from eATP sensing to synaptic and proteostatic failure
Alzheimer's disease (AD) is characterized not only by amyloid-β and tau pathology but also by progressive failure of multicellular homeostasis. The P2X7 receptor (P2X7R), a low-affinity ATP-gated ion channel preferentially activated in extracellular ATP-rich pathological microenvironments, is well positioned to translate local tissue stress into sustained glial dysfunction. Although P2X7R has traditionally been studied as a microglial inflammasome-associated receptor, its broader significance may lie in coupling microglial activation to astrocytic loss of homeostatic support. In this review, we propose an integrative model in which P2X7R functions as a high-threshold inter-glial transducer through five interconnected axes: extracellular ATP amplification, cytokine relay, extracellular vesicle exchange, convergent synaptic modulation and circuit destabilization, and a coordinated clearance-to-retention switch. Microglial P2X7R activation promotes cytokine and reactive oxygen species production, vesicle and mitochondrial release, inflammatory reprogramming, and impaired phagocytic and lysosomal competence. Astrocytic P2X7R may reinforce this environment through feed-forward ATP release, altered gliotransmission, reactive transformation, extracellular vesicle shedding, and disrupted autophagic and lysosomal processing. We further situate this reciprocal loop within the amyloid plaque niche, where dystrophic neurites, stressed synapses, and reactive glia may create a spatially restricted P2X7R-sensitive ATP microdomain. The resulting cross-glial amplification is proposed to connect neuroinflammation with synaptic destabilization and defective proteostasis. This framework also suggests that brain-penetrant and pharmacologically selective P2X7R antagonists could complement protein-targeted therapies, particularly when guided by functional biomarkers of receptor activity. However, the proposed coupling architecture remains an integrative and testable hypothesis because much of the supporting evidence derives from non-AD models, in vitro studies, or correlative human tissue analyses. Cell-type-specific, temporally resolved studies are therefore required to establish whether P2X7R-dependent microglia–astrocyte coupling causally drives AD progression.
- Open Access
- 13 May 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1827181
Convergent death programs in chronic obstructive pulmonary disease: how pyroptotic and ferroptotic crosstalk reshapes therapeutic paradigms
Chronic obstructive pulmonary disease (COPD) remains a leading cause of global mortality, yet current therapies principally target bronchodilation and broad anti-inflammatory suppression rather than the regulated cell death programs driving tissue destruction. Pyroptosis, executed through inflammasome-driven gasdermin pore formation, and ferroptosis, mediated by iron-catalyzed lipid peroxidation upon GPX4 failure, have each been implicated in COPD pathogenesis but are conventionally treated as independent processes. This review advances three original contributions. First, we map pyroptotic and ferroptotic associations across COPD inflammatory endotypes, demonstrating preferential non-canonical pyroptotic engagement in T2-low neutrophilic disease and dual death-modality involvement in T2-high eosinophilic disease. Second, we delineate a hierarchical relationship—now supported in COPD-relevant epithelial systems—in which smoke-induced Nrf2 epigenetic silencing drives ferroptotic lipid peroxide accumulation that directly triggers pyroptotic execution through caspase-11 activation, positioning GPX4 as the molecular gatekeeper. Third, we propose an inverted U-shaped model reconciling paradoxical effects of lipid peroxidation on inflammasome regulation, where membrane phospholipid hydroperoxides drive activation while free cytosolic 4-hydroxynonenal mediates suppression through covalent NLRP3 modification. We further integrate extracellular trap biology as a convergent death-associated program sharing execution machinery with pyroptosis and ferroptosis. Building on this framework, we critically appraise emerging therapeutics—including dupilumab, anti-alarmin biologics, NLRP3 inhibitors, and ferroptosis-directed agents—and propose a biomarker-guided precision medicine strategy matching cell death-targeting therapies to individual inflammatory profiles. This framework reframes COPD therapeutic design from single-pathway inhibition toward integrated modulation of interconnected death programs stratified by inflammatory endotype.
- 13 May 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1827181
Open AccessConvergent death programs in chronic obstructive pulmonary disease: how pyroptotic and ferroptotic crosstalk reshapes therapeutic paradigms
Chronic obstructive pulmonary disease (COPD) remains a leading cause of global mortality, yet current therapies principally target bronchodilation and broad anti-inflammatory suppression rather than the regulated cell death programs driving tissue destruction. Pyroptosis, executed through inflammasome-driven gasdermin pore formation, and ferroptosis, mediated by iron-catalyzed lipid peroxidation upon GPX4 failure, have each been implicated in COPD pathogenesis but are conventionally treated as independent processes. This review advances three original contributions. First, we map pyroptotic and ferroptotic associations across COPD inflammatory endotypes, demonstrating preferential non-canonical pyroptotic engagement in T2-low neutrophilic disease and dual death-modality involvement in T2-high eosinophilic disease. Second, we delineate a hierarchical relationship—now supported in COPD-relevant epithelial systems—in which smoke-induced Nrf2 epigenetic silencing drives ferroptotic lipid peroxide accumulation that directly triggers pyroptotic execution through caspase-11 activation, positioning GPX4 as the molecular gatekeeper. Third, we propose an inverted U-shaped model reconciling paradoxical effects of lipid peroxidation on inflammasome regulation, where membrane phospholipid hydroperoxides drive activation while free cytosolic 4-hydroxynonenal mediates suppression through covalent NLRP3 modification. We further integrate extracellular trap biology as a convergent death-associated program sharing execution machinery with pyroptosis and ferroptosis. Building on this framework, we critically appraise emerging therapeutics—including dupilumab, anti-alarmin biologics, NLRP3 inhibitors, and ferroptosis-directed agents—and propose a biomarker-guided precision medicine strategy matching cell death-targeting therapies to individual inflammatory profiles. This framework reframes COPD therapeutic design from single-pathway inhibition toward integrated modulation of interconnected death programs stratified by inflammatory endotype.
- Open Access
- 31 December 2024
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 12 (1) , 1-28
Decoding TDP-43: the molecular chameleon of neurodegenerative diseases
TAR DNA-binding protein 43 (TDP-43) has emerged as a critical player in neurodegenerative disorders, with its dysfunction implicated in a wide spectrum of diseases including amyotrophic lateral sclerosis (ALS), frontotemporal lobar degeneration (FTLD), and Alzheimer’s disease (AD). This comprehensive review explores the multifaceted roles of TDP-43 in both physiological and pathological contexts. We delve into TDP-43’s crucial functions in RNA metabolism, including splicing regulation, mRNA stability, and miRNA biogenesis. Particular emphasis is placed on recent discoveries regarding TDP-43’s involvement in DNA interactions and chromatin dynamics, highlighting its broader impact on gene expression and genome stability. The review also examines the complex pathogenesis of TDP-43-related disorders, discussing the protein’s propensity for aggregation, its effects on mitochondrial function, and its non-cell autonomous impacts on glial cells. We provide an in-depth analysis of TDP-43 pathology across various neurodegenerative conditions, from well-established associations in ALS and FTLD to emerging roles in diseases such as Huntington’s disease and Niemann-Pick C disease. The potential of TDP-43 as a therapeutic target is explored, with a focus on recent developments in targeting cryptic exon inclusion and other TDP-43-mediated processes. This review synthesizes current knowledge on TDP-43 biology and pathology, offering insights into the protein’s central role in neurodegeneration and highlighting promising avenues for future research and therapeutic interventions.
- 31 December 2024
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 12 (1) , 1-28
Open AccessDecoding TDP-43: the molecular chameleon of neurodegenerative diseases
TAR DNA-binding protein 43 (TDP-43) has emerged as a critical player in neurodegenerative disorders, with its dysfunction implicated in a wide spectrum of diseases including amyotrophic lateral sclerosis (ALS), frontotemporal lobar degeneration (FTLD), and Alzheimer’s disease (AD). This comprehensive review explores the multifaceted roles of TDP-43 in both physiological and pathological contexts. We delve into TDP-43’s crucial functions in RNA metabolism, including splicing regulation, mRNA stability, and miRNA biogenesis. Particular emphasis is placed on recent discoveries regarding TDP-43’s involvement in DNA interactions and chromatin dynamics, highlighting its broader impact on gene expression and genome stability. The review also examines the complex pathogenesis of TDP-43-related disorders, discussing the protein’s propensity for aggregation, its effects on mitochondrial function, and its non-cell autonomous impacts on glial cells. We provide an in-depth analysis of TDP-43 pathology across various neurodegenerative conditions, from well-established associations in ALS and FTLD to emerging roles in diseases such as Huntington’s disease and Niemann-Pick C disease. The potential of TDP-43 as a therapeutic target is explored, with a focus on recent developments in targeting cryptic exon inclusion and other TDP-43-mediated processes. This review synthesizes current knowledge on TDP-43 biology and pathology, offering insights into the protein’s central role in neurodegeneration and highlighting promising avenues for future research and therapeutic interventions.
- Open Access
- 30 July 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1450704
Unlocking the therapeutic potential of P2X7 receptor: a comprehensive review of its role in neurodegenerative disorders
The P2X7 receptor (P2X7R), an ATP-gated ion channel, has emerged as a crucial player in neuroinflammation and a promising therapeutic target for neurodegenerative disorders. This review explores the current understanding of P2X7R’s structure, activation, and physiological roles, focusing on its expression and function in microglial cells. The article examines the receptor’s involvement in calcium signaling, microglial activation, and polarization, as well as its role in the pathogenesis of Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and amyotrophic lateral sclerosis. The review highlights the complex nature of P2X7R signaling, discussing its potential neuroprotective and neurotoxic effects depending on the disease stage and context. It also addresses the development of P2X7R antagonists and their progress in clinical trials, identifying key research gaps and future perspectives for P2X7R-targeted therapy development. By providing a comprehensive overview of the current state of knowledge and future directions, this review serves as a valuable resource for researchers and clinicians interested in exploring the therapeutic potential of targeting P2X7R for the treatment of neurodegenerative disorders.
- 30 July 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1450704
Open AccessUnlocking the therapeutic potential of P2X7 receptor: a comprehensive review of its role in neurodegenerative disorders
The P2X7 receptor (P2X7R), an ATP-gated ion channel, has emerged as a crucial player in neuroinflammation and a promising therapeutic target for neurodegenerative disorders. This review explores the current understanding of P2X7R’s structure, activation, and physiological roles, focusing on its expression and function in microglial cells. The article examines the receptor’s involvement in calcium signaling, microglial activation, and polarization, as well as its role in the pathogenesis of Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and amyotrophic lateral sclerosis. The review highlights the complex nature of P2X7R signaling, discussing its potential neuroprotective and neurotoxic effects depending on the disease stage and context. It also addresses the development of P2X7R antagonists and their progress in clinical trials, identifying key research gaps and future perspectives for P2X7R-targeted therapy development. By providing a comprehensive overview of the current state of knowledge and future directions, this review serves as a valuable resource for researchers and clinicians interested in exploring the therapeutic potential of targeting P2X7R for the treatment of neurodegenerative disorders.
- 21 June 2023
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 43 (7) , 3191-3210
Microglial Metabolic Reprogramming: Emerging Insights and Therapeutic Strategies in Neurodegenerative Diseases
Microglia, the resident immune cells of the central nervous system, play a critical role in maintaining brain homeostasis. However, in neurodegenerative conditions, microglial cells undergo metabolic reprogramming in response to pathological stimuli, including Aβ plaques, Tau tangles, and α-synuclein aggregates. This metabolic shift is characterized by a transition from oxidative phosphorylation (OXPHOS) to glycolysis, increased glucose uptake, enhanced production of lactate, lipids, and succinate, and upregulation of glycolytic enzymes. These metabolic adaptations result in altered microglial functions, such as amplified inflammatory responses and diminished phagocytic capacity, which exacerbate neurodegeneration. This review highlights recent advances in understanding the molecular mechanisms underlying microglial metabolic reprogramming in neurodegenerative diseases and discusses potential therapeutic strategies targeting microglial metabolism to mitigate neuroinflammation and promote brain health. Graphical Abstract Microglial Metabolic Reprogramming in Neurodegenerative Diseases This graphical abstract illustrates the metabolic shift in microglial cells in response to pathological stimuli and highlights potential therapeutic strategies targeting microglial metabolism for improved brain health.
- 21 June 2023
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 43 (7) , 3191-3210
Microglial Metabolic Reprogramming: Emerging Insights and Therapeutic Strategies in Neurodegenerative Diseases
Microglia, the resident immune cells of the central nervous system, play a critical role in maintaining brain homeostasis. However, in neurodegenerative conditions, microglial cells undergo metabolic reprogramming in response to pathological stimuli, including Aβ plaques, Tau tangles, and α-synuclein aggregates. This metabolic shift is characterized by a transition from oxidative phosphorylation (OXPHOS) to glycolysis, increased glucose uptake, enhanced production of lactate, lipids, and succinate, and upregulation of glycolytic enzymes. These metabolic adaptations result in altered microglial functions, such as amplified inflammatory responses and diminished phagocytic capacity, which exacerbate neurodegeneration. This review highlights recent advances in understanding the molecular mechanisms underlying microglial metabolic reprogramming in neurodegenerative diseases and discusses potential therapeutic strategies targeting microglial metabolism to mitigate neuroinflammation and promote brain health. Graphical Abstract Microglial Metabolic Reprogramming in Neurodegenerative Diseases This graphical abstract illustrates the metabolic shift in microglial cells in response to pathological stimuli and highlights potential therapeutic strategies targeting microglial metabolism for improved brain health.
- 1 August 2020
- Published by Elsevier in Experimental Cell Research
- Vol. 393 (1) , 112037
Nuclear HMGB1 promotes the phagocytic ability of macrophages
- 1 August 2020
- Published by Elsevier in Experimental Cell Research
- Vol. 393 (1) , 112037
Nuclear HMGB1 promotes the phagocytic ability of macrophages
- 1 April 2014
- Published by Wolters Kluwer Health
- Vol. 31 (2) , 242-6
[Application of multiplex PCR for the screening of genotyping system for the rare blood groups Fy(a-), s-,k-,Di(b-) and Js(b-)].
To screen rare blood groups Fy(a-), s-, k-, Di(b-) and Js(b-) in an ethnic Zhuang population. Sequence-specific primers were designed based on single nucleotide polymorphism (SNP) sites of blood group antigens Fy(b) and s. A specific multiplex PCR system I was established. Multiplex PCR system II was applied to detect alleles antigens Di(b), k, Js(b)1910 and Js(b) 2019 at the same time. The two systems was were used to screen for rare blood group antigens in 4490 randomly selected healthy donors of Guangxi Zhuang ethnic origin. We successfully made the multiplex PCR system I. We detected the rare blood group antigens using the two PCR system. There are five Fy(a-), three s(-), two Di(b-) in 4490 Guangxi zhuang random samples. The multiplex PCR system I has achieved good accuracy and stability. With multiplex PCR systems I and II, 4490 samples were screened. Five Fy(a-), three s(-) and two Di(b-) samples were discovered. Multiplex PCR is an effective methods, which can be used for high throughput screening of rare blood groups. The rare blood types of Guangxi Zhuang ethnic origin obtained through the screening can provide valuable information for compatible blood transfusion. Through screening we obtained precious rare blood type materials which can be used to improve the capability of compatible infusion and reduce the transfusion reactions.
- 1 April 2014
- Published by Wolters Kluwer Health
- Vol. 31 (2) , 242-6
[Application of multiplex PCR for the screening of genotyping system for the rare blood groups Fy(a-), s-,k-,Di(b-) and Js(b-)].
To screen rare blood groups Fy(a-), s-, k-, Di(b-) and Js(b-) in an ethnic Zhuang population. Sequence-specific primers were designed based on single nucleotide polymorphism (SNP) sites of blood group antigens Fy(b) and s. A specific multiplex PCR system I was established. Multiplex PCR system II was applied to detect alleles antigens Di(b), k, Js(b)1910 and Js(b) 2019 at the same time. The two systems was were used to screen for rare blood group antigens in 4490 randomly selected healthy donors of Guangxi Zhuang ethnic origin. We successfully made the multiplex PCR system I. We detected the rare blood group antigens using the two PCR system. There are five Fy(a-), three s(-), two Di(b-) in 4490 Guangxi zhuang random samples. The multiplex PCR system I has achieved good accuracy and stability. With multiplex PCR systems I and II, 4490 samples were screened. Five Fy(a-), three s(-) and two Di(b-) samples were discovered. Multiplex PCR is an effective methods, which can be used for high throughput screening of rare blood groups. The rare blood types of Guangxi Zhuang ethnic origin obtained through the screening can provide valuable information for compatible blood transfusion. Through screening we obtained precious rare blood type materials which can be used to improve the capability of compatible infusion and reduce the transfusion reactions.
- 1 January 2014
- Published by China Science Publishing & Media Ltd. in Acta Psychologica Sinica
- Vol. 46 (11) , 1760
Interpersonal Cooperation and Conflict Influenced Outcome Evaluation in Social Decision-making
- 1 January 2014
- Published by China Science Publishing & Media Ltd. in Acta Psychologica Sinica
- Vol. 46 (11) , 1760
Interpersonal Cooperation and Conflict Influenced Outcome Evaluation in Social Decision-making